Samsung Bioepis released its Third Quarter 2025 United States Biosimilar Market Report today, providing an insight into industry pricing trends, dynamics and the Most-Favored-Nation (MFN) policy, according to a news release.
“When we first launched this report in Q2 2023, the US market had seen the approval of 40 biosimilars, with 28 products commercially launched,” Thomas Newcomer, vice president and head of U.S. commercial operations at Samsung Bioepis, said in the news release. “As of this tenth edition, the numbers have risen to 75 approvals and 53 launches, reflecting the market’s accelerating pace and growing complexity.”
In Q2, two biosimilars were approved by the FDA—Starjemza (ustekinumab), referencing Stelara (ustekinumab) and Jobevne (bevacizumab), referencing Avastin (bevacizumab). Four biosimilars were also launched—two in the denosumab market and two in the eculizumab market.
Read the slideshow above for the report highlights.